Clinical Trial

Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)

Study acronym: GEORGE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A single-arm open-label study assessing short-term (week 6, 16) and long-term (week 32) efficacy of guselkumab in adult participants with pyoderma gangrenosum (PG)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-08-14; most recent amendment 2026-03-04.
Status change: Not Yet Recruiting → Recruiting 2026-03-04
Trial Details
NCT Number NCT06563323
Lead Sponsor Oregon Health and Science University
Collaborators: Janssen Scientific Affairs, LLC, Ohio State University
Conditions Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin Ulcer
Enrollment 17 participants
Start Date 2025-02-01
Primary Completion 2027-08-13 (estimated)
Study Completion 2027-08-13 (estimated)
Updated on ClinicalTrials.gov 2026-03-06